To ameliorate the altered incretin effects in T2DM, glutides or the GLP-1 RAs, i.e., albiglutide (ALBI), dulaglutide (DULA), exenatide (EXE), liraglutide (LIRA), lixisenatide (LIXI) in injectable formulations, and semaglutide (SEMA) in injectable and oral formulations, are introduced as effective therapeutic approaches. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.